Linked Data API

Show Search Form

Search Results

1522764
registered interest false more like this
date less than 2022-10-17more like thismore than 2022-10-17
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Voluntary Scheme for Branded Medicines Pricing and Access more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, with reference to the Voluntary scheme for branded medicines pricing and access, whether her Department has made an assessment of the potential merits of an exemption from payments for new active substances from that scheme. more like this
tabling member constituency Harlow more like this
tabling member printed
Robert Halfon remove filter
uin 64035 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2022-10-25more like thismore than 2022-10-25
answer text <p>The Voluntary Scheme for Branded Medicines Pricing and Access includes a 36 month exemption from payments for drugs containing a new active substance, starting once the marketing authorisation has been granted. Treatment of new active substances under a future voluntary scheme is subject to negotiation.</p> more like this
answering member constituency Newark more like this
answering member printed Robert Jenrick more like this
question first answered
less than 2022-10-25T16:47:32.28Zmore like thismore than 2022-10-25T16:47:32.28Z
answering member
4320
label Biography information for Robert Jenrick more like this
tabling member
3985
label Biography information for Robert Halfon more like this
1521782
registered interest false more like this
date less than 2022-10-13more like thismore than 2022-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what plans her Department has to carry out an impact assessment on the effect of an increased voluntary scheme for branded medicine rate to a projected 23.7 per cent in 2023 upon the supply of medicines to the NHS. more like this
tabling member constituency Harlow more like this
tabling member printed
Robert Halfon remove filter
uin 62790 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2022-11-01
answer text <p>The Department has no plans to carry out an impact assessment on the 2023 payment percentage. The Department’s standard practice is to set the payment percentage based on measured sales. The payment percentage projected for 2023 is in line with Department projections shared with industry when the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) was agreed.</p><p>We have seen no evidence that increased VPAS payments have or will impact on the supply of medicines to the National Health Service. Where payment rates may put pressure on the profitability of individual products, there are provisions in the scheme for companies to apply for a price increase.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2022-11-01T12:16:12.963Zmore like thismore than 2022-11-01T12:16:12.963Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
3985
label Biography information for Robert Halfon more like this
1521787
registered interest false more like this
date less than 2022-10-13more like thismore than 2022-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will make it her policy to publish data comparing the voluntary scheme for branded medicines pricing and access repayments against leading European countries with similar access or rebate schemes in each year since 2015. more like this
tabling member constituency Harlow more like this
tabling member printed
Robert Halfon remove filter
uin 62791 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2022-10-25more like thismore than 2022-10-25
answer text <p>We have no plans to do so.</p><p>Prices paid for medicines internationally are generally confidential. It is therefore not possible to make an accurate comparison of the net price of medicines between the UK and other countries, with or without rebate rates.</p> more like this
answering member constituency Newark more like this
answering member printed Robert Jenrick more like this
question first answered
less than 2022-10-25T14:51:43.1Zmore like thisremove minimum value filter
answering member
4320
label Biography information for Robert Jenrick more like this
tabling member
3985
label Biography information for Robert Halfon more like this
1521788
registered interest false more like this
date less than 2022-10-13more like thismore than 2022-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, for what reason her Department included branded (a) generic and (b) biosimilar medicines that delivered savings to the NHS within the current voluntary scheme for branded medicines pricing and access scheme. more like this
tabling member constituency Harlow more like this
tabling member printed
Robert Halfon remove filter
uin 62792 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2022-11-01
answer text <p>Medicines which are required to be prescribed by brand name, including some branded generics and biosimilars, are not interchangeable. Therefore, competitive forces will not act in the same way as for generic medicines and price regulation is justified. The inclusion of these medicines in the Voluntary Scheme for Branded Medicines Pricing and Access was agreed with industry in 2019.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2022-11-01T12:23:25.943Zmore like thismore than 2022-11-01T12:23:25.943Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
3985
label Biography information for Robert Halfon more like this